CARDILATE 20MG 20 Milligram Tablets

국가: 아일랜드

언어: 영어

출처: HPRA (Health Products Regulatory Authority)

지금 구매하세요

제품 특성 요약 제품 특성 요약 (SPC)
26-04-2024

유효 성분:

NIFEDIPINE

제공처:

Norton Healthcare Limited T/A IVAX Pharmaceuticals UK

INN (International Name):

NIFEDIPINE

복용량:

20 Milligram

약제 형태:

Tablets

처방전 유형:

Product subject to prescription which may be renewed (B)

승인 상태:

Withdrawn

승인 날짜:

2010-09-14

제품 특성 요약

                                IRISH MEDICINES BOARD ACTS 1995 AND 2006
MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007
(S.I. NO.540 OF 2007)
PA0282/070/002
Case No: 2069219
The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to
NORTON HEALTHCARE LIMITED T/A IVAX PHARMACEUTICALS UK
REGENT HOUSE, 5-7 BROADHURST GARDENS, SWISS COTTAGE, LONDON NW6 3RZ, UNITED KINGDOM
an authorisation, subject to the provisions of the said Regulations, in respect of the product
CARDILATE 20MG PROLONGED- RELEASE TABLET
The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as
may be specified in the said Regulations as listed on the reverse of this document.
This authorisation, unless previously revoked, shall continue in force from 08/09/2009.
Signed on behalf of the Irish Medicines Board this
________________
A person authorised in that behalf by the said Board.
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 08/09/2009_
_CRN 2069219_
_page number: 1_
PART II
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Cardilate 20 mg Prolonged-Release Tablet
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Active ingredient: Nifedipine 20mg.
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Prolonged-Release Tablet
Round, biconvex, red-brownish coated tablets embossed with notch and ‘20’. 
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Cardilate is indicated for the treatment of mild to moderate hypertension and for prophylaxis of chronic stable angina
pectoris.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
ADULTS:
Cardilate is suitable for long-term tr
                                
                                전체 문서 읽기
                                
                            

이 제품과 관련된 검색 알림